Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry.

Esmé Kamphuis Celeste M Boesjes Laura Loman Daphne S Bakker Mila Poelhekken Nicolaas P A Zuithoff Marijke Kamsteeg Geertruida L E Romeijn Femke Van Wijk Marjolein de Bruin-Weller Marlies de Graaf Marie-Louise A Schuttelaar

Published in: Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2022)

Dupilumab treatment significantly improved disease severity and disease-associated symptoms and decreased severity-associated serum biomarkers in pediatric AD patients in daily practice.

Keyphrases

atopic dermatitis
primary care
end stage renal disease
healthcare
physical activity
newly diagnosed
ejection fraction
chronic kidney disease
quality improvement
prognostic factors
peritoneal dialysis
combination therapy
patient reported outcomes
young adults
double blind